Moderna inks licensing deal with Harbour to develop nucleic acid-based immunotherapies
hapabapa


Harbour BioMed said its unit Nona Biosciences signed a licensing and collaboration agreement with Moderna (NASDAQ:MRNA).
The companies will work on discovering and developing nucleic acid-based immunotherapies for select oncology targets using Harbour's proprietary heavy chain only antibody discovery platform (HCAb).

After execution of an agreement, Moderna will be granted an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from the HCAb platform to develop products using nucleic acids.
Harbour said Moderna will take up full responsibility for all upcoming development, manufacturing, regulatory, and commercialization activities.
Moderna would also be granted an option to get an exclusive sub-licensable license to exploit sequences against additional targets, Harbour added.
In return, Nona will get an upfront payment, and potential regulatory, development and sales milestone payments, plus royalties.